Payment overview · 2025
General Payments
$223.91
11 reported records · 8 companies
Healthcare provider profile · identity verified
Jeffrey Ray Williams, DO
Allopathic & Osteopathic Physicians|Internal Medicine · DOUGLASVILLE, GA · NPI 1972098614
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Ray Williams, DO received $223.91 in general payments during 2025 across 11 reported records.
Abbott Laboratories accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $52.65 | 23.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.40 | 19.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.62 | 15.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.63 | 15.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.06 | 6.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.91 | 6.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.70 | 6.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.94 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $223.91 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $52.65 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $43.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.63 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 368 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 122 |
| Losartan Potassium | Losartan Potassium | 236 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 72 |
| Gabapentin | Gabapentin | 170 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 50 |
| Metformin Hcl | Metformin Hcl | 140 | 56 |
| Lisinopril | Lisinopril | 139 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 58 |
| Pioglitazone Hcl | Pioglitazone Hcl | 134 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 29 |
| Omeprazole | Omeprazole | 124 | 51 |
| Metformin Hcl Er | Metformin Hcl | 122 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 41 |
| Jardiance | Empagliflozin | 95 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 47 |
| Trazodone Hcl | Trazodone Hcl | 93 | 40 |
| Alprazolam | Alprazolam | 88 | 22 |
| Clonazepam | Clonazepam | 85 | 16 |
| Mounjaro | Tirzepatide | 85 | 24 |
| Carvedilol | Carvedilol | 84 | 35 |
| Ezetimibe | Ezetimibe | 84 | 36 |
| Tramadol Hcl | Tramadol Hcl | 82 | 18 |
| Meloxicam | Meloxicam | 77 | 28 |
| Ozempic | Semaglutide | 77 | 24 |
| Potassium Chloride | Potassium Chloride | 74 | 30 |
| Alendronate Sodium | Alendronate Sodium | 69 | 27 |
| Chlorthalidone | Chlorthalidone | 69 | 27 |
| Farxiga | Dapagliflozin Propanediol | 66 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 24 |
| Allopurinol | Allopurinol | 61 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 26 |
| Sertraline Hcl | Sertraline Hcl | 57 | 23 |
| Bupropion Xl | Bupropion Hcl | 55 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 29 |
| Simvastatin | Simvastatin | 54 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 20 |
| Pregabalin | Pregabalin | 53 | 14 |
| Rybelsus | Semaglutide | 53 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 16 |
| Buspirone Hcl | Buspirone Hcl | 48 | 14 |
| Celecoxib | Celecoxib | 47 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Prednisone | Prednisone | 37 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 17 |
| Furosemide | Furosemide | 35 | 18 |
| Irbesartan | Irbesartan | 35 | 13 |
| Atenolol | Atenolol | 34 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 34 | suppressed |
| Kerendia | Finerenone | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | 11 |
| Donepezil Hcl | Donepezil Hcl | 31 | 15 |
| Finasteride | Finasteride | 30 | 12 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 13 |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | 11 |
| Torsemide | Torsemide | 27 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Eliquis | Apixaban | 25 | 11 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 13 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $223.91 · 11 records | Abbott Laboratories | AREXVY, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, General - Pain Management, JARDIANCE, OFEV, REXULTI, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error